Clearwater Health Services Clinic Clinic/Center - Rural Health Medicare: Not Enrolled in Medicare Practice Location: 123 4th St Nw, Bagley, MN 56621 Phone: 218-694-2384 Fax: 218-694-6687 |
Essentia Health Bagley Clinic Clinic/Center - Rural Health Medicare: Medicare Enrolled Practice Location: 121 Central St W, Bagley, MN 56621 Phone: 218-694-6281 Fax: 218-694-6283 |
Sanford Bagley Clinic Clinic/Center - Rural Health Medicare: Medicare Enrolled Practice Location: 1656 Central St W, Bagley, MN 56621 Phone: 218-694-2384 Fax: 218-694-6687 |
News Archive
When it comes to how much end-of-life care a patient with cancer receives, geography may, indeed, be destiny, according to new research led by Harvard Medical School that found striking differences in terminal care across different parts of the country.
A new genetic study has provided the most solid evidence to date that a low vitamin D level plays a causal role in the development of high blood pressure (hypertension).
Researchers in the United States have found that drinking coffee does not increase the risk of heart attacks in women.
The Wall Street Journal reports on the recent shutdown of a counterfeit drug ring in Syria, while highlighting a broader problem with counterfeit medicines in the Middle East. Authorities intercepted "millions of dollars worth of breast cancer, leukemia and other medicines … At least 65 people were detained; it couldn't be learned if they were charged. A trial date hasn't yet been set," according to the newspaper, which notes that the drug ring distributor's activities had also penetrated into some public health systems, "particularly in Iraq."
ConjuChem Biotechnologies Inc. announced today that the U.S. Patent & Trademark Office (USPTO) has issued a Right of Appeal Notice (Final Office Action) in the inter partes reexamination of Patent No. 6,924,264. The patent, entitled "Modified Exendins and Exendin Agonists," was issued in August 2005 and is assigned to Amylin Pharmaceuticals, Inc. The Action once again rejected all the subject claims for obviousness and/or lack of novelty. The inter partes reexamination in the USPTO does not involve any of ConjuChem's patents.
› Verified 2 days ago